Advertisement

Topics

ASCO 2017 – Lung Cancer – What is PFS2 in Advanced NSCLC, and Should we Care? Unique Analysis of the KEYNOTE-024 trial

11:00 EDT 18 Aug 2017 | GRACE

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss What is PFS2 in Advanced NSCLC, and Should we Care? A Unique Analysis of the KEYNOTE-024 Trial.

Original Article: ASCO 2017 – Lung Cancer – What is PFS2 in Advanced NSCLC, and Should we Care? Unique Analysis of the KEYNOTE-024 trial

NEXT ARTICLE

More From BioPortfolio on "ASCO 2017 – Lung Cancer – What is PFS2 in Advanced NSCLC, and Should we Care? Unique Analysis of the KEYNOTE-024 trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...